- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1552 |
Product Name |
ADT1552-Risankizumab Biosimilar-(IL23A)-Research Biosimilar Antibody |
Clonity |
Monoclonal |
|
Alternate Names anti-IL13a antibody, anti IL13a antibody, recombinant IL13a, IL13a antibody, anti-IL13a monoclonal antibody, IL13a antibodies, IL13a recombinant antibody, IL13a blocking antibody
|
|
Alias |
BI 655066, risankizumab-rzaa |
Host |
CHO Cells |
Species |
Human |
Target |
IL23A |
Gene ID |
51561 |
Isotype |
IgG1 Kappa |
Size |
100ug, 1mg, 5mg |
Research Area |
Immunology |
CAS Number |
1612838-76-2 |
Chemical Formula |
C6476H9992N1720O2016S44 |
Product Description |
Risankizumab, sold under the brand name Skyrizi, is a humanized monoclonal antibody targeting interleukin 23A (IL-23A). Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie. |
Mechanism of Action |
Risankizumab acts to prevent the release of pro-inflammatory cytokines and chemokines that often lead to inflammatory skin symptoms, such as redness, pain, and plaques. Risankizumab binds with a high affinity to the p19 subunit of human interleukin 23 (IL-23) cytokine, thereby preventing its action on the IL-23 receptor. IL-23 is a cytokine released in the human body that is involved in inflammatory and immune processes, especially in peripheral tissues.
|
Metabolism |
The metabolic pathway of risankizumab has not been characterized. As a humanized IgG1 monoclonal antibody, risankizumab is likely to be catabolized into small peptides and amino acids in the same way as endogenous IgG.
|
Application |
ELISA, WB |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reference |
1. Gaffen, S. L. (2009). “Structure and signaling in the IL-17 receptor family.” Nature Reviews Immunology, 9(8), 556-567.
2. Zheng, Y., et al. (2007). “Interleukin-23 and its role in the pathogenesis of autoimmune diseases.” Nature Reviews Immunology, 7(9), 681-693.
3. Kryczek, I., et al. (2008). “IL-23 and IL-17 in the pathogenesis of autoimmune disease.” Nature Reviews Immunology, 8(9), 681-693.
|